Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027911 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00027911 is a Phase 1 study that was terminated before completion, run by Columbia University.
The verdict
NCT00027911, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarcoma. PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with sargramostim in treating patients who have stage II, stage III, or stage IV soft tissue sarcoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL NY-ESO-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027911
The ClinicalTrials.gov registry entry for NCT00027911 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00027911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027911 about?
NCT00027911 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarco...
What is the current status of trial NCT00027911?
This trial is currently terminated. It is a Phase 1 study. The study started on 2001-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00027911?
The interventions under investigation include: sargramostim (BIOLOGICAL), NY-ESO-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027911?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.